Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oramed Pharmaceuticals Inc. (ORMP : NSDQ)
 
 • Company Description   
Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered in Jerusalem, Israel.

Number of Employees: 13

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.57 Daily Weekly Monthly
20 Day Moving Average: 865,255 shares
Shares Outstanding: 38.56 (millions)
Market Capitalization: $176.24 (millions)
Beta: 2.02
52 Week High: $31.54
52 Week Low: $3.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.38% -27.28%
12 Week -56.72% -53.23%
Year To Date -68.00% -62.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1185 AVENUE THIRD FLOOR
-
NEW YORK,NY 10036
USA
ph: 844-967-2633
fax: 972-2566-0004
ir@oramed.com http://www.oramed.com
 
 • General Corporate Information   
Officers
Nadav Kidron - President and Chief Executive Officer and Director
David Silberman - Chief Financial Officer
Aviad Friedman - Director
Miriam Kidron - Director
Arie Mayer - Director

Peer Information
Oramed Pharmaceuticals Inc. (BJCT)
Oramed Pharmaceuticals Inc. (CADMQ)
Oramed Pharmaceuticals Inc. (APNO)
Oramed Pharmaceuticals Inc. (UPDC)
Oramed Pharmaceuticals Inc. (IMTIQ)
Oramed Pharmaceuticals Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 68403P203
SIC: 2834
Fiscal Year
Fiscal Year End: August
Last Reported Quarter: 11/01/21
Next Expected EPS Date: 05/17/22
Share - Related Items
Shares Outstanding: 38.56
Most Recent Split Date: (:1)
Beta: 2.02
Market Capitalization: $176.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/17/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.02
Price/Cash Flow: -
Price / Sales: 65.20
EPS Growth
vs. Year Ago Period: 4.35%
vs. Previous Quarter: -4.76%
Sales Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -1.32%
ROE
02/28/22 - -
11/30/21 - -24.20
08/31/21 - -33.78
ROA
02/28/22 - -
11/30/21 - -21.70
08/31/21 - -28.59
Current Ratio
02/28/22 - -
11/30/21 - 19.89
08/31/21 - 14.27
Quick Ratio
02/28/22 - -
11/30/21 - 19.89
08/31/21 - 14.27
Operating Margin
02/28/22 - -
11/30/21 - -908.55
08/31/21 - -822.72
Net Margin
02/28/22 - -
11/30/21 - -908.55
08/31/21 - -822.72
Pre-Tax Margin
02/28/22 - -
11/30/21 - -944.03
08/31/21 - -850.50
Book Value
02/28/22 - -
11/30/21 - 4.48
08/31/21 - 3.58
Inventory Turnover
02/28/22 - -
11/30/21 - -
08/31/21 - -
Debt-to-Equity
02/28/22 - -
11/30/21 - 0.00
08/31/21 - 0.00
Debt-to-Capital
02/28/22 - -
11/30/21 - 0.00
08/31/21 - 0.00
 

Powered by Zacks Investment Research ©